The answer would help us understand the interaction between ERβ and TLR4 in tumor progression more clearly and provide evidence for a new therapeutic strategy for clinical patients suffering from advanced metastatic NSCLC. The gene discussed is ESR2; the disease is non-small cell lung carcinoma.